Identification

Name
Zomepirac
Accession Number
DB04828
Type
Small Molecule
Groups
Withdrawn
Description

Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

Structure
Thumb
Synonyms
  • 5-(4-Chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid
  • Zomepiracum
Product Ingredients
IngredientUNIICASInChI Key
Zomepirac sodiumDA5B6IWF46 64092-48-4SEEXPXUCHVGZGU-UHFFFAOYSA-M
Zomepirac sodium dihydrateY0185WZ209 64092-49-5Not applicable
Categories
UNII
822G987U9J
CAS number
33369-31-2
Weight
Average: 291.73
Monoisotopic: 291.066221026
Chemical Formula
C15H14ClNO3
InChI Key
ZXVNMYWKKDOREA-UHFFFAOYSA-N
InChI
InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)
IUPAC Name
2-[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]acetic acid
SMILES
CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1

Pharmacology

Indication

Zomepirac was indicated for the management of mild to severe pain.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProstaglandin D2 receptor 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Zomepirac is combined with 5-androstenedione.Experimental, Illicit
AbciximabZomepirac may increase the anticoagulant activities of Abciximab.Approved
AcebutololZomepirac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Acemetacin.Approved
AcenocoumarolZomepirac may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zomepirac.Approved, Vet Approved
AclarubicinZomepirac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Zomepirac.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.Approved
AliskirenZomepirac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alminoprofen.Experimental
AlprenololZomepirac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Zomepirac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Amcinonide.Approved
AmikacinZomepirac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideZomepirac may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Zomepirac can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinZomepirac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodZomepirac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Zomepirac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Zomepirac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Anisodamine.Investigational
annamycinZomepirac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zomepirac.Approved
Antithrombin III humanZomepirac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanZomepirac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apocynin.Investigational
ApramycinZomepirac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Zomepirac can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinZomepirac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinZomepirac may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanZomepirac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololZomepirac may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Atamestane.Investigational
AtazanavirThe metabolism of Zomepirac can be decreased when combined with Atazanavir.Approved, Investigational
AtenololZomepirac may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Zomepirac can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zomepirac.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zomepirac.Approved
BalsalazideZomepirac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminZomepirac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololZomepirac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinZomepirac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Zomepirac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zomepirac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zomepirac.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zomepirac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Betamethasone.Approved, Vet Approved
BetaxololZomepirac may decrease the antihypertensive activities of Betaxolol.Approved
BevantololZomepirac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zomepirac.Approved, Investigational
BisoprololZomepirac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinZomepirac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Zomepirac can be decreased when combined with Boceprevir.Withdrawn
BopindololZomepirac may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Zomepirac can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Zomepirac can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zomepirac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bucillamine.Investigational
BucindololZomepirac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bufexamac.Experimental
BufuralolZomepirac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Bumadizone.Experimental
BumetanideZomepirac may decrease the diuretic activities of Bumetanide.Approved
BupranololZomepirac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Zomepirac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zomepirac.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Zomepirac.Approved
CarbamazepineThe metabolism of Zomepirac can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Zomepirac is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zomepirac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Zomepirac.Approved, Vet Approved, Withdrawn
CarteololZomepirac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolZomepirac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zomepirac.Experimental
CeliprololZomepirac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Zomepirac can be increased when it is combined with Ceritinib.Approved
CertoparinZomepirac may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zomepirac.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zomepirac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zomepirac.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zomepirac.Approved
CinoxacinZomepirac may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidZomepirac may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Zomepirac can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Zomepirac can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Zomepirac.Vet Approved
CloranololZomepirac may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Zomepirac can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Zomepirac can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Zomepirac can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Zomepirac can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Zomepirac is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zomepirac.Experimental
CyclosporineZomepirac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Zomepirac is combined with D-Limonene.Investigational
Dabigatran etexilateZomepirac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Zomepirac can be decreased when it is combined with Dabrafenib.Approved
DalteparinZomepirac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidZomepirac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanZomepirac may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Zomepirac can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Zomepirac can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinZomepirac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Zomepirac can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Zomepirac.Experimental
DelavirdineThe metabolism of Zomepirac can be decreased when combined with Delavirdine.Approved
DesirudinZomepirac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zomepirac.Approved
DextranZomepirac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Zomepirac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Zomepirac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Zomepirac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinZomepirac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zomepirac.Approved, Vet Approved
DicoumarolZomepirac may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zomepirac.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Zomepirac.Approved
DihydroergotamineThe metabolism of Zomepirac can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinZomepirac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe metabolism of Zomepirac can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Zomepirac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zomepirac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Zomepirac.Approved
DoxorubicinZomepirac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Zomepirac can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Zomepirac can be decreased when combined with Dronedarone.Approved
DrospirenoneZomepirac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Zomepirac is combined with E-6201.Investigational
Edetic AcidZomepirac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanZomepirac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Zomepirac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Zomepirac.Approved
EnoxacinZomepirac may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinZomepirac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Zomepirac.Experimental
EnzalutamideThe serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide.Approved
EpanololZomepirac may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Zomepirac is combined with Epirizole.Approved
EpirubicinZomepirac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneZomepirac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zomepirac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zomepirac.Approved
EquileninThe risk or severity of adverse effects can be increased when Zomepirac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Equilin.Approved
ErythromycinThe metabolism of Zomepirac can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololZomepirac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone sulfate.Approved
Etacrynic acidZomepirac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Zomepirac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ethenzamide.Experimental
Ethyl biscoumacetateZomepirac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etofenamate.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Zomepirac is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zomepirac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Zomepirac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Feprazone.Experimental
Ferulic acidZomepirac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zomepirac.Approved
FleroxacinZomepirac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Zomepirac.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with fluasterone.Investigational
FluconazoleThe metabolism of Zomepirac can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fludrocortisone.Approved
FluindioneZomepirac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineZomepirac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Zomepirac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zomepirac.Approved, Investigational
FluvoxamineThe metabolism of Zomepirac can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zomepirac.Approved, Nutraceutical, Vet Approved
FondaparinuxZomepirac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumZomepirac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Zomepirac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Zomepirac can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zomepirac can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zomepirac.Approved
FosphenytoinThe metabolism of Zomepirac can be increased when combined with Fosphenytoin.Approved
FramycetinZomepirac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideZomepirac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Zomepirac can be increased when it is combined with Fusidic Acid.Approved
GabexateZomepirac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinZomepirac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinZomepirac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Zomepirac.Approved, Withdrawn
GemifloxacinZomepirac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinZomepirac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinZomepirac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AZomepirac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Zomepirac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinZomepirac may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Zomepirac is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Zomepirac is combined with HE3286.Investigational
HeparinZomepirac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Higenamine.Investigational
HydralazineZomepirac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zomepirac.Approved
Hygromycin BZomepirac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zomepirac.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Zomepirac is combined with Icatibant.Approved
IdarubicinZomepirac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Zomepirac can be increased when it is combined with Idelalisib.Approved
IdraparinuxZomepirac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zomepirac.Approved, Investigational
ImatinibThe metabolism of Zomepirac can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Zomepirac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.Approved
IndenololZomepirac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Zomepirac can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zomepirac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indoprofen.Withdrawn
INNO-206Zomepirac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.Approved, Investigational
IsavuconazoniumThe metabolism of Zomepirac can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinZomepirac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Zomepirac can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Zomepirac is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Zomepirac can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zomepirac can be increased when it is combined with Ivacaftor.Approved
KanamycinZomepirac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Zomepirac can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zomepirac.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zomepirac.Approved
LabetalolZomepirac may decrease the antihypertensive activities of Labetalol.Approved
LandiololZomepirac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Zomepirac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Zomepirac.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Zomepirac.Approved, Investigational
LepirudinZomepirac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanZomepirac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololZomepirac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinZomepirac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Zomepirac.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Zomepirac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Zomepirac.Approved
LonazolacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lonazolac.Experimental
LopinavirThe metabolism of Zomepirac can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.Approved
LovastatinThe metabolism of Zomepirac can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zomepirac.Approved, Investigational
LuliconazoleThe serum concentration of Zomepirac can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Zomepirac can be increased when combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Zomepirac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zomepirac.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zomepirac.Approved
ME-609The risk or severity of adverse effects can be increased when Zomepirac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zomepirac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zomepirac.Approved
MelagatranZomepirac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zomepirac.Approved, Vet Approved
MepindololZomepirac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineZomepirac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Zomepirac.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Zomepirac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololZomepirac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.Approved
MetoprololZomepirac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideZomepirac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinZomepirac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifepristoneThe serum concentration of Zomepirac can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zomepirac.Approved
MitotaneThe serum concentration of Zomepirac can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Zomepirac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zomepirac.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zomepirac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.Approved
NadololZomepirac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinZomepirac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatZomepirac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Zomepirac.Approved
Nalidixic AcidZomepirac may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Zomepirac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Zomepirac is combined with NCX 1022.Investigational
NeamineZomepirac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe metabolism of Zomepirac can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Zomepirac can be decreased when combined with Nelfinavir.Approved
NemonoxacinZomepirac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinZomepirac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nepafenac.Approved
NetilmicinZomepirac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Zomepirac can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Zomepirac can be increased when combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zomepirac.Approved
NilotinibThe metabolism of Zomepirac can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zomepirac.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nitroaspirin.Investigational
NorfloxacinZomepirac may increase the neuroexcitatory activities of Norfloxacin.Approved
OlaparibThe metabolism of Zomepirac can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zomepirac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.Approved
OlsalazineZomepirac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Zomepirac.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Zomepirac can be increased when it is combined with Osimertinib.Approved
OtamixabanZomepirac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zomepirac.Approved
Oxolinic acidZomepirac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololZomepirac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac.Withdrawn
PalbociclibThe serum concentration of Zomepirac can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Paramethasone.Approved
ParomomycinZomepirac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Parthenolide.Investigational
PazufloxacinZomepirac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinZomepirac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololZomepirac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Zomepirac can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateZomepirac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Zomepirac.Approved
PhenindioneZomepirac may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Zomepirac can be increased when combined with Phenobarbital.Approved
PhenprocoumonZomepirac may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zomepirac.Approved, Vet Approved
PhenytoinThe metabolism of Zomepirac can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zomepirac.Approved, Investigational
PindololZomepirac may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidZomepirac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinZomepirac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideZomepirac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirfenidone.Investigational
Piromidic acidZomepirac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zomepirac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirprofen.Experimental
PlazomicinZomepirac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinZomepirac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zomepirac.Approved
PosaconazoleThe metabolism of Zomepirac can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololZomepirac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Zomepirac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Zomepirac can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Zomepirac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Propacetamol.Approved
PropranololZomepirac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Zomepirac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Zomepirac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Zomepirac.Vet Approved
Protein CZomepirac may increase the anticoagulant activities of Protein C.Approved
Protein S humanZomepirac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeZomepirac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinZomepirac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Zomepirac is combined with PTC299.Investigational
PuromycinZomepirac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Zomepirac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zomepirac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Zomepirac.Approved
RanolazineThe metabolism of Zomepirac can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zomepirac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zomepirac.Experimental, Investigational
ReviparinZomepirac may increase the anticoagulant activities of Reviparin.Approved
RibostamycinZomepirac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe metabolism of Zomepirac can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Zomepirac can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Zomepirac can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Risedronate.Approved, Investigational
RitonavirThe metabolism of Zomepirac can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanZomepirac may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinZomepirac may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinZomepirac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinZomepirac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Zomepirac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Zomepirac.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Zomepirac.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zomepirac.Experimental
SaquinavirThe metabolism of Zomepirac can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Zomepirac.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Zomepirac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Zomepirac is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Zomepirac can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Zomepirac can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Zomepirac can be increased when it is combined with Simeprevir.Approved
SisomicinZomepirac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinZomepirac may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Zomepirac.Approved
SotalolZomepirac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CZomepirac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinZomepirac may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinZomepirac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Zomepirac.Approved
SpironolactoneZomepirac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Zomepirac is combined with SRT501.Investigational
St. John's WortThe serum concentration of Zomepirac can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Zomepirac can be increased when it is combined with Stiripentol.Approved
StreptomycinZomepirac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinZomepirac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zomepirac.Approved
SulfisoxazoleThe metabolism of Zomepirac can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Zomepirac.Approved
SulodexideZomepirac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Zomepirac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zomepirac.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Suxibuzone.Experimental
TacrolimusZomepirac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Zomepirac.Approved
TalinololZomepirac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Zomepirac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zomepirac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Zomepirac can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Zomepirac can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zomepirac.Approved, Investigational
TemafloxacinZomepirac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Zomepirac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zomepirac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Teriflunomide.Approved
TertatololZomepirac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zomepirac.Approved
TiclopidineThe metabolism of Zomepirac can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tiludronic acid.Approved, Vet Approved
TimololZomepirac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tixocortol.Approved
TobramycinZomepirac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Zomepirac can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zomepirac.Approved
TorasemideZomepirac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Zomepirac.Approved
TranilastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zomepirac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zomepirac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneZomepirac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zomepirac.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triptolide.Investigational
TrovafloxacinZomepirac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinZomepirac may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Zomepirac.Approved
ValrubicinZomepirac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Zomepirac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Zomepirac.Approved
VenlafaxineThe metabolism of Zomepirac can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Zomepirac can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Zomepirac can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinZomepirac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranZomepirac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Zomepirac.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Zomepirac can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Zomepirac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zoledronic acid.Approved
Zoptarelin doxorubicinZomepirac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinZomepirac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

James B. Doherty, Debra L. Allison, "Process for the preparation of zomepirac and related compounds." U.S. Patent US4374997, issued January, 1978.

US4374997
General References
Not Available
External Links
PubChem Compound
5733
PubChem Substance
46504549
ChemSpider
5531
BindingDB
50027952
ChEBI
35859
ChEMBL
CHEMBL19490
PharmGKB
PA166049188
HET
ZOM
Wikipedia
Zomepirac
ATC Codes
M01AB04 — Zomepirac
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)178.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP3.37ALOGPS
logP3.33ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.86ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity77.2 m3·mol-1ChemAxon
Polarizability29.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9714
Blood Brain Barrier+0.8608
Caco-2 permeable+0.7695
P-glycoprotein substrateNon-substrate0.7316
P-glycoprotein inhibitor INon-inhibitor0.9347
P-glycoprotein inhibitor IINon-inhibitor0.9287
Renal organic cation transporterNon-inhibitor0.7965
CYP450 2C9 substrateNon-substrate0.7288
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5337
CYP450 1A2 substrateNon-inhibitor0.7776
CYP450 2C9 inhibitorNon-inhibitor0.8844
CYP450 2D6 inhibitorNon-inhibitor0.8955
CYP450 2C19 inhibitorNon-inhibitor0.7741
CYP450 3A4 inhibitorNon-inhibitor0.8973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8525
Ames testNon AMES toxic0.8817
CarcinogenicityNon-carcinogens0.8425
BiodegradationNot ready biodegradable0.9476
Rat acute toxicity2.7638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9389
hERG inhibition (predictor II)Non-inhibitor0.8816
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Benzoyl derivatives / Chlorobenzenes / N-methylpyrroles / Aryl chlorides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Aryl-phenylketone / Benzoyl / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Substituted pyrrole / N-methylpyrrole
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, monochlorobenzenes, aromatic ketone, pyrroles (CHEBI:35859 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Pritchard JF, O'Neill PJ, Affrime MB, Lowenthal DT: Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding. Clin Pharmacol Ther. 1983 Nov;34(5):681-8. [PubMed:6627828 ]
  2. Ojingwa JC, Spahn-Langguth H, Benet LZ: Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm. 1994 Feb;22(1):19-40. [PubMed:8027947 ]

Drug created on September 11, 2007 14:33 / Updated on October 18, 2017 17:26